Understanding the Burden of Facial Involvement in Atopic Dermatitis
Key Takeaways
- In French adults with physician-confirmed atopic dermatitis, POEM global-severity and BoFA facial-burden measures were moderately correlated.
- The authors describe psychosocial burden as comparable between patients classified as clear or almost clear globally but with severe facial involvement and those with moderate-to-severe disease without facial involvement.
- Within the facial-involvement subgroup, facial burden was the stronger independent correlate of stigmatization, while POEM was not independently significant after adjustment.
Investigators conducted the cross-sectional observational VISEABLE atopic dermatitis phenotyping study in 1,400 French adults with physician-confirmed atopic dermatitis (AD). POEM, a global symptom-severity measure, classified participants as clear or almost clear (0–7) or moderate to severe (≥8). BoFA measured facial burden on a 0–109 scale, with 36 as the threshold for severe facial involvement. Crossing the global-severity strata with absent, milder, or severe facial involvement defined six phenotypes. Stigmatization and life-trajectory impact were psychosocial outcomes, and investigators modeled stigmatization in a regression restricted to participants with facial involvement.
Global severity and facial burden were moderately correlated (Pearson r=0.365). The compared groups were described as Ph3, combining clear or almost clear POEM severity with severe facial involvement, and Ph4, combining moderate-to-severe POEM severity with no facial involvement. For the group described as Ph3, reported PUSH-d stigmatization and DLLIM life-trajectory impact scores were 21.93 and 14.76, respectively. The authors describe psychosocial burden as comparable between patients with milder global disease and severe facial involvement and those with moderate-to-severe disease without facial involvement.
Among participants with facial involvement, higher BoFA scores remained significantly associated with stigmatization after adjustment (β=11.44; partial R²=46.2%). POEM was not independently statistically significant in the same regression. This comparison of independent correlates was confined to participants with facial involvement, rather than all phenotypes in the cohort.
Cross-sectional observations establish contemporaneous associations and group comparisons, not whether facial involvement caused psychosocial burden. The findings concern French adults with physician-confirmed AD and do not establish whether the same phenotype pattern would appear in a U.S. population.
The authors interpret the findings as showing that severe facial involvement can accompany substantial psychosocial burden, even when global symptoms place a patient in a milder category.
Clinician Questions
Why did VISEABLE use a BoFA threshold of 36 to classify facial involvement in atopic dermatitis?
Among French adults with physician-confirmed atopic dermatitis, that threshold was the study population’s median facial-burden score and helped organize the POEM-by-facial-burden phenotypes; it was not presented as a universal clinical cutoff.
Does the stigmatization regression for facial atopic dermatitis apply to adults without facial involvement?
No. The regression comparing BoFA and POEM as independent predictors of stigmatization included only participants with facial involvement; it does not establish the same relationship among adults without facial involvement.
Recommended Reading
- For more on facial AD burden: Treating Atopic Dermatitis in Sensitive and High-Impact Areas